Mirum Pharmaceuticals (MIRM) Receives a Buy From Evercore ISI
FDA Approves Mirum Pharma's Livmarli Tablet Formulation For Treatment Of Cholestatic Pruritus In Patients With Alagille Syndrome And Progressive Familial Intrahepatic Cholestasis
Express News | Mirum Pharmaceuticals Inc - Livmarli Tablets to Be Available in June
Express News | Mirum’s Livmarli Now FDA Approved in Tablet Formulation
Express News | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Cuts Target Price to $53
Does Mirum Pharmaceuticals (NASDAQ:MIRM) Have A Healthy Balance Sheet?
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $74
Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus
Express News | Livmarli Now Approved in Japan for Algs and Pfic
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
Morgan Stanley Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $65
Mirum Pharmaceuticals: Promising Growth Trajectory With Strategic Focus and Pipeline Progress
Trade Alert: COO & President Of Mirum Pharmaceuticals Peter Radovich Has Sold Stock
Director's Bold Move: Major Stock Purchase in Mirum Pharmaceuticals!
Insider Sale: PRESIDENT AND COO of $MIRM Sells 1,169 Shares
Mirum Pharmaceuticals Insider Sold Shares Worth $676,928, According to a Recent SEC Filing
Analysts Have Conflicting Sentiments on These Healthcare Companies: Certara (CERT), Lantheus (LNTH) and Mirum Pharmaceuticals (MIRM)
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $55 to $74
Mirum Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations